- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Dr Andorsky on Real-World Treatment Patterns With BTK Inhibitors in CLL/SLL
David J. Andorsky, MD, discusses recently observed patterns of care with BTK inhibitors in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma in the community setting in the United States, and how social determinants of health may have affected these outcomes.
- 2x
- 1.75x
- 1.5x
- 1.25x
- 1x, selected
- 0.75x
- 0.5x
- Chapters
- descriptions off, selected
- captions settings, opens captions settings dialog
- captions off, selected
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
David J. Andorsky, MD, medical oncologist and hematologist, Rocky Mountain Cancer Centers, associate chair, US Oncology Hematology Research, discusses recently observed patterns of care with BTK inhibitors in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) in the community setting in the United States, and how social determinants of health may have affected these outcomes.
Related Content:
